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We have identified a family afflicted over multiple generations with posterior fossa tumors of infancy, including
central nervous system (CNS) malignant rhabdoid tumor (a subset of primitive neuroectodermal tumors, or PNET)
and choroid plexus carcinoma. Various hereditary tumor syndromes, including Li-Fraumeni syndrome, Gorlin
syndrome, and Turcot syndrome, have been linked to increased risk of developing CNS PNETs and choroid plexus
tumors. Malignant rhabdoid tumors of the CNS and kidney show loss of heterozygosity at chromosome 22q11.
The hSNF5 gene on chromosome 22q11 has recently been identified as a candidate tumor-suppressor gene in
sporadic CNS and renal malignant rhabdoid tumors. We describe a family in which both affected and some
unaffected family members were found to have a germline splice-site mutation of the hSNF5 gene, leading to
exclusion of exon 7 from the mature cDNA and a subsequent frameshift. Tumor tissue shows loss of the wild-
type hSNF5 allele, in keeping with a tumor-suppressor gene. These findings suggest that germline mutations in
hSNF5 are associated with a novel autosomal dominant syndrome with incomplete penetrance that predisposes to
malignant posterior fossa brain tumors in infancy.
Germline mutations in a number of genes—including
p53, (Li-Fraumeni syndrome), PATCHED, (Gorlin
syndrome), and possibly APC (Turcot syndrome)—
predispose to familial cancer syndromes that include the
development of central nervous system (CNS) primitive
neuroectodermal tumors (PNET) (Li and Fraumeni
1969; Hamilton et al. 1995; Hahn et al. 1996). PNET
neoplasms of the CNS include medulloblastoma, pi-
neoblastoma, and CNS malignant rhabdoid tumor.
Truncating mutations of the hSNF5 gene on chromo-
some 22q11.2 (MIM 601607) were recently found in
sporadic renal and CNS malignant rhabdoid tumors
(Versteege et al. 1998; Biegel et al. 1999). Several infants
with malignant rhabdoid tumors were noted to have
germline mutations of the hSNF5 gene, but in no case
Received January 7, 2000: accepted for publication January 27,
2000; electronically published March 14, 2000.
Address for correspondence and reprints: Dr. James T. Rutka, Arthur
and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick
Children, University of Toronto, 3008b McMaster Building, 88
Elm Street, Toronto, Ontario M4N 1X8, Canada. E-mail: rutka
@sickkids.on.ca
 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6604-0022$02.00
could a mutation of hSNF5 be found in the parents of
affected children, nor were there signs of affected indi-
viduals in other generations. Other reports have sug-
gested the existence of familial syndromes that predis-
pose to the development of malignant rhabdoid tumors
(Lynch et al. 1983; Bonnin et al. 1984; Fort et al. 1994;
Parellada et al. 1998). The hSNF5 protein is part of a
multiprotein complex that functions to remodel nucle-
osomes and thus to regulate the access of transcription
factors to a number of different promoters. The mech-
anism by which loss of hSNF5 leads to neoplasia is
unknown.
We report a family afflicted by posterior fossa brain
tumors over at least two generations. The proband pre-
sented at age 18 mo with a cerebellar malignant rhab-
doid tumor. Both of the parents are healthy, but the
proband’s maternal uncle died at age 2 years from a
posterior fossa choroid plexus carcinoma (fig. 1). The
maternal grandfather’s sibling died, as an infant, from
a disease process consistent with a pediatric brain tumor.
Tissue from the maternal grandfather’s sibling is not
available for analysis. The occurrence of two posterior
fossa tumors of infancy in one family is a rare event and
may suggest a germline mutation predisposing to ma-
1404 Am. J. Hum. Genet. 66:1403–1406, 2000
Figure 1 Pedigree showing posterior fossa tumors in one family
over two generations with an unaffected carrier.
Figure 2 RT-PCR of a portion of the hSNF5 cDNA, showing
the expected wild-type product from normal brain and from paternal
and sibling (brother) wbc cDNA. Maternal and proband wbc cDNA
shows wild-type and mutant transcripts, with an intervening hetero-
duplex. Tumor cDNA shows only the mutant transcript, with loss of
the wild-type allele.
lignancy. We hypothesized that this family might harbor
a germline mutation in the hSNF5 gene, accounting for
the high incidence of malignancy observed.
Informed consent was obtained from all family mem-
bers, and approval for genetic testing was obtained from
the Institutional Research Ethics Board of the Hospital
for Sick Children, University of Toronto. Parents of the
proband received genetic counseling before and after
learning the results of this study. Genomic DNA was
isolated from peripheral blood leukocytes (white blood
cells [wbc]) by standard techniques. Lymphocytes were
separated from peripheral blood by gradient centrifu-
gation through a percoll gradient, and RNA was ex-
tracted with Trizol (Gibco BRL). The proband’s brain
tumor was flash frozen in liquid nitrogen in the operating
room, and RNA and DNA were extracted with Trizol.
Paraffin sections of the uncle’s tumor were digested over-
night in proteinase K for extraction of genomic DNA.
Overlapping primer pairs were used to amplify por-
tions of the hSNF5 cDNA by PCR, and the products
were analyzed by agarose gel electrophoresis, to assess
for the presence of aberrant transcripts. Primer SSNF5-
5R (CGC GGA TCT TCT TCT CCAT) was used to
sequence normal and mutant transcripts amplified from
tumor and control cDNA. Primers (ssnf57-2f: GAG TTT
GTC ACC ACC ATC G) and (ssnf5-7-2R: GAG CAA
ACA CAC AGA CC) were used to amplify exon 7 and
surrounding intronic sequences from genomic DNA.
PCR products were sequenced by cycle sequencing using
Thermo Sequenase (USB). In addition, the entire coding
region of hSNF5 (mutant and wild-type transcripts) was
amplified from maternal cDNA with use of the forward
primer (5′-ccggaatccgccgcctctgccgccgcaatg-3′) and the re-
verse primer (5′-ccggaattcccaggccgggcccgtgttggcaagacg-
3) and cloned into the EcoR1 site of pBluescript. Full-
length and mutant clones were sequenced on a Li-Cor
automated sequencer with the T7 and T3 primers.
Analysis of the reverse transcriptase (RT)-PCR prod-
ucts from one of the hSNF5 primer pairs revealed an
aberrant transcript in the proband, her tumor, and ma-
ternal cDNA (fig. 2). This product was seen in neither
paternal cDNA nor cDNA from normal brain tissue
from an unrelated individual. Although lymphocyte
cDNA from the proband and her mother show both the
expected wild-type product and the aberrant transcript,
tumor cDNA shows only the aberrant product with loss
of wild-type product, consistent with the role of hSNF5
as a tumor-suppressor gene. Sequencing of wild-type and
truncated transcripts amplified by RT-PCR revealed the
truncated product to be hSNF5 but to lack the portion
of the cDNA corresponding to exon 7 (data not shown).
This leads to joining of exon 6 to exon 8 with a sub-
sequent frameshift and generation of a premature stop
codon. RT-PCR of the full-length hSNF5 gene from ma-
ternal cDNA revealed two products: the expected wild-
type 1200-bp product and a truncated 1,000-bp prod-
uct. Other than the lack of exon 7, the sequence of this
hSNF5 allele contained no other mutations (data not
shown). Sequencing of exon 7 and surrounding intronic
sequences from genomic DNA revealed a GrA mutation
in the donor splice site of exon 7. This mutation alters
the conserved GT sequence at the beginning of the intron
and thus violates the GT rule for splice-site recognition.
This mutation was seen in genomic DNA from the pro-
band, her tumor, maternal DNA, and DNA from the
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Figure 3 Sequencing of exon 7 of hSNF5, showing a GrA mutation (double arrow) in the proband’s tumor, proband’s germline, and
mother’s germline DNA. Leukocyte DNA from proband’s father and brother show the wild-type sequence. The proband’s tumor and her uncle’s
tumor (Uncle) show the same GrA mutation.
uncle’s tumor (fig. 3). Although lymphocyte samples
show heterozygosity with preservation of the wild-type
allele, both tumor specimens show only the mutant al-
lele, consistent with loss of heterozygosity (LOH) at this
locus, typical of a tumor-suppressor gene.
This splice mutation is predicted to cause a truncation
of the protein and likely contributes to the high incidence
of posterior fossa brain tumors seen in this family. The
proband’s tumor shows LOH for chromosome 22, as
has been described in malignant rhabdoid tumors (Biegel
et al. 1990, 1996). This particular mutation in hSNF5
shows incomplete penetrance, because the proband’s
mother is completely unaffected. Whether the mother
has an increased risk of developing a malignancy in the
future is uncertain; however, both choroid plexus car-
cinoma and CNS malignant rhabdoid tumors are un-
common in adults. Although hSNF5 mutations have
been described in renal rhabdoid tumors, only CNS tu-
mors were seen in this kindred. Whether germlinehSNF5
mutations predispose specifically to CNS tumors re-
quires description of further families with germline mu-
tations. The region of the hSNF5 protein deleted in this
family includes the second highly conserved repeat re-
gion as well as the C terminal coiled-coil region (Mu-
chardt et al. 1995; Morozov et al. 1998). The c-myc
oncogene is amplified in many medulloblastomas, and
c-myc has been shown to bind to the hSNF5 protein
(Bigner et al. 1990; Cheng et al. 1999). This interaction
would be predicted to be preserved in the family de-
scribed in the present report. Malignant rhabdoid tu-
mors are a subset of CNS PNETs only recently differ-
entiated from medulloblastoma (Rorke et al. 1996).
PNETs and choroid plexus carcinoma are tumor types
known to occur in the Li-Fraumeni syndrome. Although
this family does not meet the criteria for a diagnosis of
either Li-Fraumeni syndrome or Li-Fraumeni–like syn-
drome, other such families in which a p53 mutation is
not found may have germline hSNF5 mutations.
In conclusion, we describe a family affected over at
least two generations with posterior fossa brain tumors
of infancy, in whom we have characterized a germline
mutation in the hSNF5 gene. The absence of symptoms
in the proband’s unaffected mother suggests that this
mutation can show incomplete penetrance. Families with
an increased incidence of pediatric brain tumors may
harbor germline mutations in the hSNF5 gene.
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